IP Library Granted Patent US 7,968,283
Granted Patent B2
US 7,968,283 · App. 12/825,078 · Granted Jun 28, 2011

Gene expressed in prostate cancer

Assignee: Agensys, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,283
App. No.
12/825,078
Granted
Jun 28, 2011
Kind
B2
Abstract

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

Claims (10)

1. A method of detecting the presence of a protein in a test sample, comprising:

providing the test sample;

contacting the test sample with a monoclonal antibody or antigen binding fragment thereof that binds the protein, which comprises the amino acid sequence of SEQ ID NO.2; and

detecting the binding of the protein in the test sample thereto, wherein detection of the protein correlates to the presence of a prostate cancer cell in the test sample.

2. The method of claim 1 , wherein the monoclonal antibody or antigen binding fragment thereof is labeled with a detectable marker.

3. The method of claim 2 , wherein the detectable marker is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator and an enzyme.

4. An in vitro method of delivering a detectable marker to a prostate cancer cell that expresses a protein comprising the amino acid sequence of SEQ ID NO:2, comprising:

providing a monoclonal antibody or antigen binding thereof that binds specifically to the protein, wherein the antibody or antigen binding is labeled with the detectable marker; and

contacting the cell with the antibody or antigen binding thereof such that the detectable marker is delivered.

5. The in vitro method of claim 4 , wherein the detectable marker is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator and an enzyme.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2011
From: AFAR, DANIEL E.H.; HUBERT, RENE S.; MITCHEL, STEPHEN C.
To: UROGENESYS
Reel/Frame 025861/0369 →
CHANGE OF NAME Recorded Feb 24, 2011
From: UROGENESYS, INC.
To: AGENSYS, INC.
Reel/Frame 025862/0820 →
Continuity (6)
Division 12211702 · Sep 16, 2008
Division 10334561 · Dec 30, 2002
Division 09410132 · Sep 30, 1999
Provisional Application 60146584 · Jul 28, 1999
Provisional Application 60102572 · Sep 30, 1998
Related Publication 20100303845A1 · Dec 2, 2010